Key terms
About PEPG
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PEPG news
Mar 13
7:22am ET
PepGen receives Orphan Drug, Rare Pediatric Disease designations for PGN-EDO51
Mar 12
6:09am ET
3 Best Stocks to Buy Now, 3/12/2024, According to Top Analysts
Mar 11
10:15pm ET
Stifel Nicolaus Reaffirms Their Buy Rating on PepGen Inc. (PEPG)
Mar 08
2:05am ET
3 Best Stocks to Buy Now, 3/8/2024, According to Top Analysts
Mar 07
6:17pm ET
PepGen treatment of Duchenne Muscular Dystrophy gets FDA orphan designation
Mar 07
8:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Generation Bio (GBIO), PepGen Inc. (PEPG)
Mar 07
8:17am ET
PepGen price target lowered to $20 from $21 at Wedbush
Mar 07
6:30am ET
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), iTeos Therapeutics (ITOS) and Rezolute (RZLT)
Mar 06
11:20pm ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (PEPG), BridgeBio Pharma (BBIO) and Amedisys (AMED)
Mar 04
7:04am ET
PepGen announces clearance of CTA by U.K. MHRA to begin CONNECT2-EDO51
Feb 20
8:15am ET
PepGen Earns FDA Fast Track Status for Myotonic Dystrophy Drug
Feb 20
8:05am ET
PepGen receives U.S. Fast Track designation for PGN-EDODM1
Feb 08
4:08am ET
PepGen Inc. Announces Pricing for Its Offering
Feb 08
4:08am ET
PepGen Inc. Secures Funding to Advance Research Programs
Feb 07
7:34am ET
PepGen prices 7.53M shares at $10.635 in underwritten public offering
Jan 31
5:27am ET
Buy Rating Affirmed for PepGen Inc. on Strong Prospects in DMD Treatment and Promising EDO Platform
Jan 31
12:50am ET
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), Crispr Therapeutics AG (CRSP) and BridgeBio Pharma (BBIO)
Jan 30
10:59am ET
PepGen Inc trading resumes
Jan 30
10:49am ET
PepGen Inc trading halted, volatility trading pause
Jan 17
7:03am ET
PepGen appoints DeLena as General Counsel, Secretary
Jan 11
1:40am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (PEPG), Viridian Therapeutics (VRDN) and Blueprint Medicines (BPMC)
Jan 08
7:41am ET
PepGen announces first patient dosed in CONNECT1-EDO51 Phase 2 trial
No recent press releases are available for PEPG
PEPG Financials
Key terms
Ad Feedback
PEPG Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PEPG Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
